pentamidine has been researched along with Myotonic Dystrophy in 8 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Myotonic Dystrophy: Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1)." | 8.31 | Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. ( Boschi, F; Briançon, S; Calderan, L; Carras, J; Carton, F; Galiè, M; Jacquier, A; Lollo, G; Malatesta, M; Perduca, M; Repellin, M; Schaeffer, L, 2023) |
| "In a context of drug repurposing, pentamidine (PTM), an FDA-approved antiparasitic drug, has been proposed to reverse the splicing defects associated in myotonic dystrophy type 1 (DM1)." | 4.31 | Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy. ( Boschi, F; Briançon, S; Calderan, L; Carras, J; Carton, F; Galiè, M; Jacquier, A; Lollo, G; Malatesta, M; Perduca, M; Repellin, M; Schaeffer, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, TL | 1 |
| Mayence, A | 1 |
| Vanden Eynde, JJ | 1 |
| Repellin, M | 1 |
| Carton, F | 1 |
| Boschi, F | 1 |
| Galiè, M | 1 |
| Perduca, M | 1 |
| Calderan, L | 1 |
| Jacquier, A | 1 |
| Carras, J | 1 |
| Schaeffer, L | 1 |
| Briançon, S | 1 |
| Lollo, G | 1 |
| Malatesta, M | 1 |
| Yenigun, VB | 1 |
| Sirito, M | 1 |
| Amcheslavky, A | 1 |
| Czernuszewicz, T | 1 |
| Colonques-Bellmunt, J | 1 |
| García-Alcover, I | 1 |
| Wojciechowska, M | 1 |
| Bolduc, C | 1 |
| Chen, Z | 1 |
| López Castel, A | 1 |
| Krahe, R | 1 |
| Bergmann, A | 1 |
| Neaga, IO | 1 |
| Hambye, S | 1 |
| Bodoki, E | 1 |
| Palmieri, C | 1 |
| Ansseau, E | 1 |
| Belayew, A | 1 |
| Oprean, R | 1 |
| Blankert, B | 1 |
| Coonrod, LA | 1 |
| Nakamori, M | 2 |
| Wang, W | 1 |
| Carrell, S | 1 |
| Hilton, CL | 1 |
| Bodner, MJ | 1 |
| Siboni, RB | 1 |
| Docter, AG | 1 |
| Haley, MM | 1 |
| Thornton, CA | 2 |
| Berglund, JA | 2 |
| Chakraborty, M | 1 |
| Selma-Soriano, E | 1 |
| Magny, E | 1 |
| Couso, JP | 1 |
| Pérez-Alonso, M | 1 |
| Charlet-Berguerand, N | 1 |
| Artero, R | 1 |
| Llamusi, B | 1 |
| Warf, MB | 1 |
| Matthys, CM | 1 |
| Cooper, TA | 1 |
1 review available for pentamidine and Myotonic Dystrophy
| Article | Year |
|---|---|
Some non-conventional biomolecular targets for diamidines. A short survey.
Topics: Amidines; Animals; Diabetes Mellitus, Type 2; DNA; Enzymes; Humans; Hypertension; Ion Channels; Myot | 2014 |
7 other studies available for pentamidine and Myotonic Dystrophy
| Article | Year |
|---|---|
Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy.
Topics: Humans; Hyaluronic Acid; Muscle, Skeletal; Myotonic Dystrophy; Pentamidine | 2023 |
(CCUG)
Topics: Animals; Apoptosis; Disease Models, Animal; DNA Repeat Expansion; Drosophila melanogaster; Drosophil | 2017 |
Affinity capillary electrophoresis for identification of active drug candidates in myotonic dystrophy type 1.
Topics: Benzamidines; Drug Evaluation, Preclinical; Electrophoresis, Capillary; HeLa Cells; Humans; Ligands; | 2018 |
Reducing levels of toxic RNA with small molecules.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Female; Male; Mice; Myotonic Dystrophy; Pentamidin | 2013 |
Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Diastole; Disease Models, Animal; Drosophila melanogaster; Drosophila | 2015 |
Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Topics: Alternative Splicing; Animals; Disease Models, Animal; HeLa Cells; Humans; Mice; Myotonic Dystrophy; | 2009 |
Chemical reversal of the RNA gain of function in myotonic dystrophy.
Topics: Alternative Splicing; Animals; Disease Models, Animal; Humans; Mice; Myotonic Dystrophy; Pentamidine | 2009 |